be used topically as a solution, dispersion, powder, or in the form of microspheres. The polyclonal antibody is preferably a recombinant polyclonal antibody produced by phage display technology. The pairing of specific immunoglobulin variable region light chain and heavy chain maintained from the original polyclonal immune response or selected by panning using the allergen in question is preferably maintained by bulk transfer of the pairs into an expression vector.

In the Claims:

Please replace claims 1 and 10 with the following amended claims that have been re-written in clean form.

1. (Amended) A pharmaceutical composition comprising as an active ingredient a recombinant polyclonal antibody capable of reacting with or binding to proteins or epitopes derived from an inhaled, ingested, or airborne allergen, together with one or more pharmaceutically acceptable excipients.

10. (Amended) A pharmaceutical composition according to claim 1, wherein the recombinant polyclonal antibody is generated by phage display technology.

Please add the following new claims 35-49.

35. (New) A pharmaceutical composition according to claim 1, wherein said polyclonal antibody is an IgG antibody.

36. (New) A pharmaceutical composition according to claim 1, wherein said polyclonal antibody is an IgM antibody.

37. (New) A pharmaceutical composition according to claim 1, wherein said polyclonal antibody is an IgA antibody.

38. (New) A pharmaceutical composition according to claim 1, wherein said polyclonal antibody is an IgD antibody.

39. (New) A pharmaceutical composition according to claim 1, wherein said polyclonal antibody has antibody molecules from a mixture of antibody classes.

40. (New) A pharmaceutical composition according to claim 1, wherein said polyclonal antibody binds said allergen with sufficient density to mediate the elimination of said allergen from a patient.

41. (New) A pharmaceutical composition according to claim 1, wherein said polyclonal antibody binds said allergen with a higher antibody density than a monoclonal antibody.

42. (New) A pharmaceutical composition according to claim 1, wherein said polyclonal antibody does not cross-react with endogenous self-antigens in a patient.

43. (New) A pharmaceutical composition according to claim 1, wherein said polyclonal antibody does not elicit an anaphylactic response in humans.

44. (New) A pharmaceutical composition according to claim 1, wherein said polyclonal antibody is a fully human antibody.

45. (New) A pharmaceutical composition according to claim 1, wherein the variable region of said polyclonal antibody has a mutation.

46. (New) A pharmaceutical composition according to claim 1, wherein at least 85% of the antibody molecules in said composition are target-specific.

47. (New) A pharmaceutical composition according to claim 1, wherein at least 90% of the antibody molecules in said composition are target-specific.

48. (New) A pharmaceutical composition according to claim 1, wherein said polyclonal antibody is a complete antibody molecule or fragment thereof such as an F_{ab} fragment.

49. (New) A pharmaceutical composition according to claim 1, wherein said composition is provided as a microsphere, liposome, polyethylene glycol-conjugated complex, or complex of positively or negatively charged excipients with antibody molecules of the opposite charge, wherein said composition prolongs the clearance of said polyclonal antibody in a patient.